Levetiracetam Induced Behavioural Changes in an Adult Female Patient: A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
H. A. Virani, Hetal Kantilal Dabhi, P. Pargi
{"title":"Levetiracetam Induced Behavioural Changes in an Adult Female Patient: A Case Report.","authors":"H. A. Virani, Hetal Kantilal Dabhi, P. Pargi","doi":"10.2174/0115748863285429240326172920","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nLevetiracetam, a relatively recent addition to antiepileptic medications, is known for its broad-spectrum efficacy in treating partial and generalized tonic-clonic seizures in individuals of all age groups. Despite its favourable tolerability profile, rare instances of psychiatric side effects have been reported. This case study presents a rare occurrence of significant behavioural changes attributed to levetiracetam in a young female patient.\n\n\nCASE HISTORY\nA 40-year-old woman with a long-standing history of epilepsy, well-managed with medication, presented with abrupt-onset behavioural changes, including irritability, aggression, crying spells, insomnia, increased talkativeness, and screaming. Notably, these behavioural changes were unrelated to seizure activity and emerged without precedent. A dose reduction of levetiracetam was also attempted, which proved ineffective in mitigating her symptoms.\n\n\nCONCLUSION\nConsequently, the drug was discontinued, resulting in the resolution of the behavioural symptoms. This case highlights levetiracetam as the likely causative factor behind the observed significant behavioural changes.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863285429240326172920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Levetiracetam, a relatively recent addition to antiepileptic medications, is known for its broad-spectrum efficacy in treating partial and generalized tonic-clonic seizures in individuals of all age groups. Despite its favourable tolerability profile, rare instances of psychiatric side effects have been reported. This case study presents a rare occurrence of significant behavioural changes attributed to levetiracetam in a young female patient. CASE HISTORY A 40-year-old woman with a long-standing history of epilepsy, well-managed with medication, presented with abrupt-onset behavioural changes, including irritability, aggression, crying spells, insomnia, increased talkativeness, and screaming. Notably, these behavioural changes were unrelated to seizure activity and emerged without precedent. A dose reduction of levetiracetam was also attempted, which proved ineffective in mitigating her symptoms. CONCLUSION Consequently, the drug was discontinued, resulting in the resolution of the behavioural symptoms. This case highlights levetiracetam as the likely causative factor behind the observed significant behavioural changes.
一名成年女性患者的左乙拉西坦诱发行为改变:病例报告。
背景左乙拉西坦是抗癫痫药物中相对较新的一种,因其在治疗各个年龄组的部分性和全身性强直-阵挛发作方面具有广谱疗效而闻名。尽管其耐受性良好,但也有罕见的精神副作用报道。本病例研究介绍了一名年轻女性患者因服用左乙拉西坦而出现明显行为改变的罕见病例。病例一名 40 岁女性患者有长期癫痫病史,药物治疗效果良好,但突然出现行为改变,包括易怒、攻击性、哭闹、失眠、多言和尖叫。值得注意的是,这些行为变化与癫痫发作活动无关,而且是在没有先例的情况下出现的。因此,她停用了左乙拉西坦,结果行为症状得到缓解。本病例突出表明,左乙拉西坦可能是导致所观察到的明显行为变化的致病因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信